摘要: Methods for treating a human with lymphoma using combination of interleukin-2 and at least one anti-CD20 antibody are provided. These therapeutic agents administered as two separate pharmaceutical compositions, containing IL-2, the other antibody, according to dosing regimen. Administering these together potentiates effectiveness either agent alone, resulting in positive response that is improved respect observed alone. The effects can be achieved lower dosages thereby lessening toxicity prolonged IL-2 administration potential tumor escape.
glgoo.top参考文章(13)
Michael Kunitani, Flint Smith, Robert F. Halenbeck, Process for recovering microbially produced interleukin-2 ,(1988)
Marc D. Whitlow, David R. Filpula, Linker for linked fusion polypeptides ,(1993)
Joseph D. Rosenblatt, Maurice J. Wolin, Methods of therapy for non-hodgkin's lymphoma using a combination_of an antibody to cd20 and interleuking-2 ,(2001)
Robert Zimmerman, Jeffrey L. Winkelhake, Combination therapy using interleukin-2 and tumor necrosis factor ,(1994)
Todd A. Fehniger, James Hitt, Michael A. Caligiuri, N. J. Meropol, Grace M. Barresi, Margaret Franklin, Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunology, Immunotherapy. ,vol. 46, pp. 318- 326 ,(1998) , 10.1007/S002620050493
Gail A. Leget, Myron S. Czuczman, Use of rituximab, the new FDA-approved antibody Current Opinion in Oncology. ,vol. 10, pp. 548- 551 ,(1998) , 10.1097/00001622-199811000-00012
Robert Charles Ladner, Robert Earl Bird, Single polypeptide chain binding molecules ,(1987)
Karl Hardman, Robert E. Bird, Robert C. Ladner, Immunotheraphy using single chain polypeptide binding molecules ,(1993)
Roland A. Newman, Nabil Hanna, Ronald W. Raab, Recombinant antibodies for human therapy ,(1992)
Arthur Dale Riggs, Herbert Louis Heyneker, Ronald Burnell Wetzel, William Evans Holmes, Shmuel Cabilly, Recombinant immunoglobin preparations ,(1983)